Serum AST and ALT activities have the advantage of low cost and availability for detection of liver injury, establishing their measurement as important biomarkers in identifying the presence of liver fibrosis in T2D patients with NAFLD. The gene discussed is GPT; the disease is Hepatic fibrosis.